Duodenal ulcer

Burget DW, Chiverton SG, Hunt RH: Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990, 99(2):345–351. Hopkins RJ, Girardi LS, Turney EA: Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996, 110(4):1244–1252. Goodwin CS, Marshall BJ, Blincow ED, et al.: Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J.Clin.Pathol 1988, 41:207–210. Richardson P, Hawkey CJ, Stack WA: Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998, 56(3):307–335. Verdu EF, Armstrong D, Idstrom JP, et al.: Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995, 37:743–748. Labenz J, Tillenburg B, Peitz U, et al.: Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer [comments]. Gastroenterology 1996, 110(3):725–732. Kiilerich S, Rannem T, Elsborg L: Effect of intravenous infusion of omeprazole and ranitidine on twenty-four-hour intragastric pH in patients with a history of duodenal ulcer. Digestion 1995, 56(1):25–30. Labenz J, Peitz U, Leusing C, et al.: Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study. Gut 1997, 40:36–41. Cook D, Guyatt G, Marshall J, et al.: A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. Canadian Critical Care Trials Group. N Engl J Med 1998, 338(12):791–797. Malfertheiner P, Megraud F, O’Morain C et al.: Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group Gut 1997, 41:8–13. Excellent report outlines important guidelines established by the Helicobacter Pylori Study Group. (Published erratum appears in Gut 1997, 41(2):276). Yamada TD, Ahnen D, Alpers DH: NIH Consensus conference: Helicobacter pylori in peptic ulcer disease. JAMA 1994, 272(1):65–69. Lam SK, Talley NJ: Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol 1998, 13(1):1–12. Lam SK, Ching CK, Lai KC, et al.: Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study. Gut 1997, 41(1):43–48. Peterson WL, Ciociola AA, Sykes DL, et al.: Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. Aliment Pharmacol Ther 1996, 10(3):251–261. Hosking SW, Ling TK, Chung SC, et al.: Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 1994, 343:508–510. Huang JQ, Wilkinson JM, Hunt RH: Antimicrobials accelerate healing of duodenal ulcer (DU) when given with proton pump inhibitors (PPI) or H2-receptor antagonists (H2RA): A meta-analysis. Gut 1997, 41(1):A93. Chan FK, Sung JJ, Suen R, et al.: Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study. Aliment Pharmacol Ther 1998, 12(12):1201–1205. Hawkey CJ, Karrasch JA, Szczepanski L, et al.: Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 1998, 338(11):727–734. This study addresses the important issue of which medication is most effective in healing NSAID-associated duodenal ulcer. Yeomans ND, Tulassay Z, Juhasz L, et al.: A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 1998, 338(11):719–726. This study addresses the important issue of which medication is most effective in healing NSAID-associated duodenal ulcer. Lind T, Veldhuyzen van Zanten S, Unge P, et al.: Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996, 1:138–144. Misiewicz JJ, Harris AW, Bardhan KD, et al.: One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut 1997, 41:735–739. Laine L, Estrada R, Trujillo M, et al.: Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1996, 10:1029–1033. Cammarota G, Papa A, Cianci R, et al.: Three-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure Helicobacter pylori infection: a pilot study. Eur J Gastroenterol Hepatol 1999, 11(3):247–250. Chey WD, Fisher L, Barnett J, et al.: Low-versus highdose azithromycin triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1998, 12(12):1263–1267. Pohle T, Stoll R, Kirchner T, et al.: Eradication of Helicobacter pylori with lansoprazole, roxithromycin and metronidazole—an open pilot study. Aliment Pharmacol Ther 1998, 12(12):1273–1278. van der Hulst RWM, Keller JJ, Rauws EAJ, Tytgat GNJ: Treatment of Helicobacter pylori infection: A review of the world literature. Helicobacter 1996, 1(1):6–19. Peitz U, Hackelsberger A, Malfertheiner P: A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Drugs 1999, 57(6):905–920. Buckley MJ, Xia HX, Hyde DM, et al.: Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig Dis Sci 1997, 42(10):2111–2115. Lind T, Megraud F, Unge P, et al.: The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999, 116(2):248–253. Wurzer H, Rodrigo L, Stamler D, et al.: Short-course therapy with amoxicillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. Aliment Pharmacol Ther 1997, 11:943–952. Megraud F, Pichavant R, Palegry D, et al.: Ranitidine bismuth citrate (RBC) co-prescribed with clarithromycin is more effective in the eradication of Helicobacter pylori than omeprazole with clarithromycin. Gut 1997, 41(1):A92. Midolo PD, Lambert JR, Kerr TG, Tee W: In vitro synergy between ranitidine bismuth citrate and tetracycline or clarithromycin against resistant strains of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1999, 18(11):832–834. Sung JJ, Chan FK, Wu JC, et al.: One-week ranitidine bismuth citrate in combinations with metronidazole, amoiycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study. Aliment Pharmacol Ther 1999, 13(8):1079–1084. Bardhan KD, Wurzer H, Marcelino M, et al.: Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers [published erratum appears in Am J Gastroenterol 1999, Jan, 94(1):298]. Am J Gastroenterol 1998, 93(3):380–385. Van der Wouden EJ, Thijs JC, van Zwet AA, et al.: One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus twoweek dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial. Am J Gastroenterol 1998, 93(8):1228–1231. Mao HV, Lak BV, Long T, et al.: Omeprazole or ranitidine bismuth citrate triple therapy to treat Helicobacter pylori infection: a randomized, controlled trial in Vietnamese patients with duodenal ulcer. Aliment Pharmacol Ther 2000, 14(1):97–101. Dore MP, Sepulveda AR, Mura I, et al.: Explanation for variability of omeprazole amoxicillin therapy? Tolerance of H-pylori to amoxicillin [abstract]. Gastroenterology 1997, 112:(4)A105. Dore MP, Piana A, Carta M, et al.: Amoxicillin resistance is one reason for failure of amoxicillin-omeprazole treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1998, 12:635–639. van Zwet AA, Vandenbrouke-Grauls CM, Thijs JC, et al.: Stable amoxicillin resistance in Helicobacter pylori [letter]. Lancet 1998, 352:1595. McColl EKEL, el-Nujumi A, Murray IS, et al.: Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer. Gut 1998, 42:618–622. Phull PS, Halliday D, Price AB, Jacyna MR: Absence of dyspeptic symptoms as a test of Helicobacter pylori eradication. BMJ 1996, 312:349–350. Leodolter A, Dominguez-Munoz JE, von Arnim U, et al.: Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Am J Gastroenterol 1999, 94(8):2100–2104. Peitz U, Sulliga M, Nusch A, et al.: Randomised study on two second-line treatments after failed metronidazole-clarithromycin therapy [abstract]. Gut 1999, 45(3):A114-A114. Peitz U, Glasbrenner B, Ellenrieder V, et al.: Re-treatment of H. pylroi infection with high dose omeprazole-amoxicillin after failure with metronidazoleclarithromycin combination [abstract]. Gut 1999, 45(3):A111-A111. Bock H, Heep M, Lehn N: Rifabutin, amoxocillin, and lanzoprazole eradication of H. pylori after multiple therapy failures [abstract]. Gut 1999, 45(3):A109-A109. Perri F, Festa V, Andriulli A: Treatment of antibioticresistant Helicobacter pylori. N Engl J Med 1998, 339(1):53. Hirschowitz BI, Lanas A: Intractable upper gastrointestinal ulceration due to aspirin in patients who have undergone surgery for peptic ulcer. Gastroenterology 1998, 114(5):883–892. Excellent paper that reveals factors underlying refractory duodenal ulcer. Adamek RJ, Szymanski C, Pfaffenbach B: Pantoprazole suppresses Helicobacter pylori without affecting cure. Helicobacter 1999, 4(4):266–271. Annibale B, D’Ambra G, Luzzi I, et al.: Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? Am J Gastroenterol 1997, 92(5):790–794. Forrest JA, Finlayson ND, Shearman DJ: Endoscopy in gastrointestinal bleeding. Lancet 1974, 2(7877): 394–397. Presentation of the Forrest method of grading bleeding signs. Chung IK, Ham JS, Kim HS, et at.: Comparison of the hemostatic efficacy of the endoscopic hemoclip method with hypertonic saline-epinephrine injection and a combination of the two for the management of bleeding peptic ulcers. Gastrointest Endosc 1999, 49(1):13–8. Rutgeerts P, Rauws E, Wara P, et al.: Randomised trial of single and repeated fibrin glue compared with injection of polidocanol in treatment of bleeding peptic ulcer. Lancet 1997, 350(9079):692–696.